MAP2K7 and melanoma: BRAF and MEK combination therapy is a current standard-of-care treatment for BRAFV600 melanoma patients, and the Food and Drug Administration (FDA) has approved three combination therapies; dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib.